ADT with SBRT versus SBRT alone for hormone-sensitive oligorecurrent prostate cancer (RADIOSA): a randomised, open-label, phase 2 clinical trial
European Institute of Oncology · University of Milan · +5 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
73
total citations
- FWCI
- 84.74
- Percentile
- 100%
- References
- 26
Citations per year
Authors
26- GMGiulia MarvasoCorresponding
European Institute of Oncology, University of Milan
- GCGiulia Corrao
University of Milan, European Institute of Oncology
- MZMattia Zaffaroni
European Institute of Oncology
- MGMaria Giulia Vincini
European Institute of Oncology
- CLChiara Lorubbio
European Institute of Oncology, University of Milan
Topics & keywords
Topics
Keywords
- Prostate cancer
- Open label
- Medicine
- Oncology
- Randomized controlled trial
- Internal medicine
- Clinical trial
- Urology
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.